SCHEMBL23600199

SCHEMBL23600199

O=C1NC(=O)/C(=C/c2c[nH]c3ncccc23)O1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.56
HASPIN Q8TF76 4/20 0.56
KMT2A Q03164 1/20 0.55
CDC7 O00311 8/20 0.52
CCNT1 O60563 2/20 0.48
CDK9 P50750 2/20 0.48
PIM1 P11309 2/20 0.45
PIM2 Q9P1W9 2/20 0.45
GSK3B P49841 1/20 0.45
PIM3 Q86V86 1/20 0.43
GPR84 Q9NQS5 1/20 0.43
CHEK2 O96017 1/20 0.42
CDK1 P06493 1/20 0.42
SRC P12931 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29764667 0.79 PIM1 (0.43) CHEK1HASPINKMT2ACDC7PIM1
SCHEMBL23600433 0.79 KMT2A (0.55) CHEK1HASPINKMT2ACDC7CCNT1
SCHEMBL23600203 0.79 PIM1 (0.43) CHEK1HASPINKMT2ACDC7PIM1
SCHEMBL5576480 0.78 NTRK1 (0.53) KMT2APIM1CDK1
SCHEMBL5576481 0.78 NTRK1 (0.53) KMT2APIM1CDK1
SCHEMBL5576484 0.78 NTRK1 (0.53) KMT2APIM1CDK1
SCHEMBL23600236 0.77 HASPIN (0.54) CHEK1HASPINKMT2ACDC7CCNT1
SCHEMBL20344103 0.77 HASPIN (0.54) CHEK1HASPINKMT2ACDC7CCNT1
SCHEMBL29764697 0.76 PIM1 (0.43) CHEK1HASPINKMT2ACCNT1CDK9
SCHEMBL23600201 0.76 PIM1 (0.43) CHEK1HASPINKMT2ACCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US claimed
CN-114945569-A Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same 延世大学校产学协力团 2022-08-26 CN claimed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
EP-4083037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME Yonsei University, University-Industry Foundation(UIF). (KR) 2022-11-02 EP disclosed
WO-2021133037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME 연세대학교 산학협력단 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP CHEK1 3461/4885HASPIN 1208/4885KMT2A 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.